Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy

Author:

Owen Carolyn J.12,Toze Cynthia L.2,Koochin Anna2,Forrest Donna L.2,Smith Clayton A.2,Stevens Jane M.1,Jackson Shannon C.3,Poon Man-Chiu3,Sinclair Gary D.4,Leber Brian5,Johnson Peter R. E.6,Macheta Anthony7,Yin John A. L.8,Barnett Michael J.2,Lister T. Andrew1,Fitzgibbon Jude1

Affiliation:

1. Centre for Medical Oncology, Barts and the London School of Medicine & Dentistry, London, United Kingdom;

2. Leukemia/BMT Program of British Columbia, British Columbia Cancer Agency and Vancouver General Hospital, and University of British Columbia, Vancouver, BC;

3. Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, and Calgary Health Region, Calgary, AB;

4. Department of Biochemistry and Molecular Biology, University of Calgary, and Molecular Hematology, Calgary Laboratory Services, Calgary, AB;

5. Department of Biochemistry & Biomedical Sciences, McMaster University, Hamilton, ON;

6. Department of Haematology, Western General Hospital, Edinburgh, United Kingdom;

7. Furness General Hospital, University Hospitals of Morecambe Bay NHS Trust, Morecambe Bay, United Kingdom; and

8. University Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom

Abstract

Abstract Familial platelet disorder with propensity to myeloid malignancy (FPD/AML) is an autosomal dominant syndrome characterized by platelet abnormalities and a predisposition to myelodysplasia (MDS) and/or acute myeloid leukemia (AML). The disorder, caused by inherited mutations in RUNX1, is uncommon with only 14 pedigrees reported. We screened 10 families with a history of more than one first degree relative with MDS/AML for inherited mutations in RUNX1. Germ- line RUNX1 mutations were identified in 5 pedigrees with a 3:2 predominance of N-terminal mutations. Several affected members had normal platelet counts or platelet function, features not previously reported in FPD/AML. The median incidence of MDS/AML among carriers of RUNX1 mutation was 35%. Individual treatments varied but included hematopoietic stem cell transplantation from siblings before recognition of the inherited leukemogenic mutation. Transplantation was associated with a high incidence of complications including early relapse, failure of engraftment, and posttransplantation lymphoproliferative disorder. Given the small size of modern families and the clinical heterogeneity of this syndrome, the diagnosis of FPD/AML could be easily overlooked and may be more prevalent than previously recognized. Therefore, it would appear prudent to screen young patients with MDS/AML for RUNX1 mutation, before consideration of sibling hematopoietic stem cell transplantation.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3